Find information on thousands of medical conditions and prescription drugs.

Von Hippel-Lindau disease

Von Hippel-Lindau disease (VHL) is a rare inherited genetic condition involving the abnormal growth of tumors in parts of the body which are particularly rich in blood supply. more...

VACTERL association
Van der Woude syndrome
Van Goethem syndrome
Varicella Zoster
Variegate porphyria
Vasovagal syncope
VATER association
Velocardiofacial syndrome
Ventricular septal defect
Viral hemorrhagic fever
Vitamin B12 Deficiency
VLCAD deficiency
Von Gierke disease
Von Hippel-Lindau disease
Von Recklinghausen disease
Von Willebrand disease


Features of VHL are:

  • angiomatosis - little knots of capillaries in various organs. These tend to be cavernous hemangiomas, which are sharply defined, sponge-like tumors composed of large, dilated, cavernous vascular spaces.
  • hemangioblastomas - tumors of the central nervous system (CNS, especially the cerebellum). These tumors, whether benign (usual) or malignant (rarer), may cause problems, for example angiomas in the brain or spinal cord may press on nerve or brain tissue. As an angioma grows, the walls of the blood vessels may weaken and leak, causing damage to surrounding tissues. Blood leakage from angiomas in the retina can interfere with vision. Cysts may also grow around angiomas.
  • pheochromocytoma - tumors of the adrenal medulla that often produce catecholamines
  • renal cell carcinoma - in some forms

Untreated, VHL may result in blindness and permanent brain damage, death is usually caused by complications of malignant tumors in the brain or kidney.


There are various subtypes (see OMIM):

  • Type 1 (angiomatosis without pheochromocytoma)
  • Type 2 (angiomatosis with pheochromocytoma)
    • Type 2A (with renal cell carcinoma)
    • Type 2B (without renal cell carcinoma)
    • Type 2C (only pheochromocytoma and no angiomatosis or renal cell carcinoma)


The disease is caused by mutations of the VHL gene on the short arm of the third chromosome (3p26-p25). The resultant protein is produced in two forms, an 18 kDa and a 30 kDa protein that functions as a tumor suppressor gene. The main action of the VHL protein is thought to be its E3 ubiquitin ligase activity that results in specific target proteins being 'marked' for degradation. The most researched of these targets is hypoxia inducible factor 1a (HIF1a), a transcription factor that induces the expression of a number of angiogenesis related factors. It stands to reason that the loss of VHL protein activity results in an increased amount of HIF1a, and thus increased levels of angiongenic factors. In turn, this leads to unregulated blood vessel growth, one of the prerequesites of a tumour.

VHL is an autosomal dominant disorder, but there is a wide variation in the age of onset of the disease, the organ system affected and the severity of effect. Most people with von Hippel-Lindau syndrome inherit an altered copy of the gene from one parent. In about 20 percent of cases, however, the altered gene is the result of a new mutation that occurred during the formation of reproductive cells (eggs or sperm) or early in fetal development.

As long as one copy of the VHL gene is producing functional VHL protein in each cell, tumors do not form. If a mutation occurs in the second copy of the VHL gene during a person's lifetime, the cell will have no working copies of the gene and will produce no functional VHL protein. A lack of this protein allows tumors characteristic of von Hippel-Lindau syndrome to develop.


[List your site here Free!]

A natural liquid cartilage extract brings new hope for patients with metastatic renal cell carcinoma
From Townsend Letter for Doctors and Patients, 1/1/04 by Dominique Garrel


The latest progress and trends in antiangiogenic therapy were recently presented at the "Angiogenesis: New Opportunities & Solutions for Drug Development" meeting held on September 29-30, 2003 in Cambridge, Massachusetts. The conference featured Dr. Judah Folkman, MD, a pioneer in angiogenesis research, as keynote speaker. Biopharmaceutical leaders in the field also presented their latest reports of ongoing clinical trials. Much awaited by all attendees, were the results of a recently completed Phase III trial of a natural liquid cartilage extract (LCE) as monotherapy for stage IV metastatic renal cell carcinoma (RCC) refractory to conventional treatments. Patients enrolled in the study were stratified into four groups, according to their ECOG status (0 or 1) and the number of metastatic sites (1 or more than 1). Results from this placebo controlled, double-blind clinical trial revealed a significant survival advantage for a cohort of patients with clear cell histology, an ECOG=0, and a single metastatic site. For this preplanned group of 38 patients, oral administration of LCE more than doubled life expectancy, 26.3 months for LCE compared to 12.6 months for placebo, with a convincing p value= 0.02. For the first time ever, a group of patients with metastatic RCC refractory to the standard treatment, showed statistically significant clinical benefits with a natural product. Once again LCE confirmed its outstanding safety profile. LCE's success in such harsh conditions augurs well for its use in first line combination therapies.

Angiogenesis and tumor growth

Angiogenesis is the process through which new blood vessels form and grow. Angiogenesis is a natural physiological function which can be subverted by cancer cells to satisfy their increasing need for nutrients and oxygen as tumors grow untamed. The angiogenic process, as currently understood, can be summarized as follows: a cell activated by a lack of oxygen (or a mutation) releases, among other things, angiogenic factors that attract inflammatory and endothelial cells and promote their proliferation. In the course of their migration, inflammatory cells secrete additional substances that intensify the angiogenic call. The endothelial cells that form existing blood vessels respond to angiogenic signals in their vicinity by proliferating and secreting proteases, which break open the blood-vessel wall to enable them to migrate toward the site of the angiogenic stimuli. Proliferating endothelial cells then organize themselves into new capillary tubes by altering the arrangement of their adherence-membrane proteins. Finally, through the process of anastomosis, the capillaries emanating from the arterioles and the venules join to provide a continuous blood flow that sustains tumor cell metabolism and sets up escaping avenues for metastatic tumor cells (Fig. 1).



Modulators of angiogenesis

A variety of different growth factors and cytokines can promote angiogenesis, but one of the most important is vascular endothelial growth factor (VEGF). VEGF is a soluble protein secreted by most types of cells, except by endothelial cells themselves. On the other hand, endothelial cells express receptors for this growth factor. Hypoxic conditions, as seen in cancer growth, are a potent trigger of VEGF expression. Interaction of VEGF with its receptor induces an intracellular signaling cascade that favors endothelial cell survival, proliferation and migration and increases vascular permeability. VEGF also up-regulates the expression of other proteins involved in angiogenesis. High serum levels of VEGF correlates with poor prognosis in cancer patients.

VEGF relies on the complementary action of matrix metalloproteinases (MMPs) for the process of angiogenesis. MMPs are key proteins in the extension of the vascular bed. MMPs form a family of structurally related, zinc-dependent endopeptidases secreted by various cell types, including endothelial cells. MMPs collectively have the potential to degrade all of the protein and proteoglycan components of the extracellular matrix (ECM) surrounding cells. MMPs also influence important cellular processes and immune cell functions through proteolytic processing and shedding of bioactive molecules such as cytokines and growth factors. In the context of tumor angiogenesis, MMPs digest the blood-vessel walls enabling endothelial cells to make their way toward the tumor and providing cancer cells with breaches through which they can spread to distant organs (Fig. 2).

Advanced Renal Cell Carcinoma

Although RCC ranks only seventh among other causes of cancer and accounts for less than 3% of all malignancies, it is a deadly disease, leaving very little hope for newly diagnosed patients. Estimations for 2003 predict the discovery of 31,000 new cases in the USA and a death toll of almost 11,900 patients. There are three main reasons for such a high death rate. First, RCC is a silent disease lacking early warning signs. By the time RCC patients seek for medical advice, nearly half of them harbor locally advanced (stage III) or metastatic disease (stage IV) (see Fig. 3). Second, even early-stage RCC, that can be treated with nephrectomy, tends to progress to metastatic disease within one year of surgery. Third, advanced RCC responds very poorly to chemotherapeutic treatment (less than 10% have a partial response) and not at all to radiotherapy. Chemoresistance has been linked to the presence of efflux pumps at the surface of RCC cells (Zhang et al, 2000). Immunomodulation with interferon-alpha (IFN) and/or interleukin-2 (IL-2) is the standard treatment for advanced RCC but is hampered with a limited response rate (less than 20%) and significant toxicity. Overall, the prognosis for metastatic RCC is quite somber, with a median survival time of 6 to 12 months and a five year survival rate of less than 5% (Flanigan et al, 2003).


Antiangiogenic therapy for Renal Cell Carcinoma

The poor outcome of standard cancer therapies in advanced RCC is a big incentive for the development of newer experimental approaches. Digging into the molecular mechanisms involved in this pathology has led to the recognition of angiogenesis as a valuable target.

RCC is known to be a well vascularized tumor. A link between angiogenesis and RCC was first established when the von Hippel-Lindau (VHL) susceptibility gene was identified in patients with an inherited form of the disease (Latif et al, 1993). Subsequently, VHL mutations were found in a majority of patients with sporadic clear cell renal carcinomas (Gnarra et al, 1994). Clear cell type histology is the most common form of renal carcinoma, representing up to 80% of all RCCs, and is associated with the worst prognosis, except maybe for collecting duct carcinomas. A mutation in the VHL tumor suppressor gene is associated with the stabilization of hypoxia-inducible factor (HIF). Accumulation of HIF protein then results in increased expression of downstream target genes such as VEGF (Wiesener et al, 2001). As mentioned above, VEGF is an important component of angiogenesis and is associated with poor survival in RCCs (Jacobsen et al, 2000; Na et al, 2003; Paradis et al, 2000).

Another characteristic of RCC related to angiogenesis is its high potential to spread to distant organs. Common sites of spread include lungs (75%), soft tissues (36%), bones (20%), liver (18%), brain (8%) and subcutaneous tissue. (8%). Metastatic potential strongly relies on the stimulation of MMP activity. More specifically, expression and activity of the gelatinase subclass of MMPs (MMP2 and MMP9) are increased in RCC compared to that of normal kidney and correlate with tumor size, tumor grade and vessel invasion (Kamiya et al, 2003). Highest levels are seen in the clear cell subtype of RCC (Hagemann et al, 2001). Interestingly, clear cell RCC shows specific alterations in a subset of chromosomes, including loss of chromosome 3p which hosts the tissue inhibitor of metalloproteinase-4 (TIMP-4) gene locus (Junker et al, 1993; Olson et al 1998). In normal physiology, TIMP-4 binds to pro-MMP2, inhibiting its activation (Bigg et al, 1997). Loss of TIMP-4 may contribute to outbalance proteolytic activities in RCC.

What is clear at this point is that there are multiple pathways involved in the angiogenic and malignant processes that sustain RCC. Therefore, the ideal inhibitor of cancer angiogenesis should be able to knock down multiple mechanisms simultaneously. Angiogenesis inhibitors in clinical development, that failed so far to show any significant benefits in cancer, were handicapped by their focus on a single mechanism of the angiogenic process (Shepherd et al, 2003).


LCE: an antiangiogenic product with multiple mechanisms of action

LCE is a naturally occurring antiangiogenic compound, extracted from marine cartilage according to an exclusive patented protocol. The final product is active when taken orally (Berbari et al, 1999). While most antiangiogenic agents target only one mechanism of the very sophisticated angiogenic process, research shows that LCE acts on multiple fronts (Fig. 4).

Blocking VEGF binding and signaling

Studies revealed that LCE can interfere with the binding of VEGF to its receptor on human endothelial cells. VEGF binding normally triggers the phosphorylation of its receptor and that, in turn, initiates an intracellular cascade of signaling events leading to physiological pro-angiogenic responses. LCE inhibition of VEGF binding in vitro correlates with a significant and specific decrease in VEGF receptor phosphorylation. Downstream events such as the sprouting of small capillaries are prevented, as shown ex vivo, in an animal model of angiogenesis. It also prevents VEGF-dependent migration of endothelial cells in vitro. Furthermore, LCE oral administration reduces VEGF-induced blood vessels permeability, further attesting of its bioavailability (Beliveau et al, 2002).

Inhibiting MMPs

In vitro studies also evidenced a strong inhibition of the gelatinolytic and elastinolytic activities of MMP-2, MMP-9, and MMP-12 in the presence of LCE. These enzymes play a major role in tumor proliferation and progression. The inhibitory potential of LCE on matrix metalloproteinases was evaluated using fluorimetric assays and zymography techniques aimed at measuring the activity of different classes of these enzymes. Results were presented at the 90th American Association for Cancer Research conference in April 1999, and published by Gingras et al. in 2001.

Induction of endothelial cell specific apoptosis

Induction of endothelial cell apoptosis (programmed cell death) is a pharmacological strategy with the potential to inhibit angiogenesis (Nor and Polverini, 1999). As shown in vitro, LCE can promote endothelial cell apoptosis. This activity of LCE is specific to endothelial cells and correlates with caspase-3 and 8 activation. Induction of endothelial cell apoptosis by LCE may thus represent an additional mechanism underlying its antiangiogenic effect. Results from this study were presented at the 92nd Annual Meeting of the American Association for Cancer Research in March 2001, and published by Boivin et al. in 2002.

Increase in the level of angiostatin

Additional experimental data show that LCE is able to increase the level of angiostatin in mice with implanted human glioblastoma, a form of brain cancer. Angiostatin is a proteolytic fragment of the plasminogen that acts as a potent inhibitor of angiogenesis and tumor growth. The study consisted of injecting human glioblastoma cells (cancer cells) into the brain of nude mice. The mice were then given LCE in order to test for antitumoral activity. Not only did results evidence an antitumoral activity in LCE, but they also uncovered a new element of its mode of action. LCE apparently increases the catalytic efficiency of plasminogen activator (tPA)-mediated plasmin generation through a direct interaction with plasminogen. Increased tPA activity sustains endogenous angiostatin production at tumor site. Results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in May 2001 and have been submitted for publication (Jourdes et al, submitted; Gingras et al, submitted).

LCE is thus a natural extract that blocks several pathways involved in angiogenesis and tumor development. The multiple molecular mechanisms of action of LCE make it an ideal and pluripotent anti-angiogenic compound to help prevent tumor progression.

LCE: Phase III study in advanced stage renal cell carcinoma

LCE performed outstandingly well in pre-clinical pharmacological studies both in vitro and in vivo, revealing potent anti-angiogenic activity without any evidence of toxicity. On the basis of these promising preliminary results, studies progressed to the clinic. The therapeutic potential of LCE has been investigated in oncology, dermatology and ophthalmology (Sauder et al, 2002; Batist et al, 2002; Bukowski, 2003; Latreille et al, submitted). Over 900 patients have been treated with LCE in Canada and the United States, some for more than five years.

The encouraging results of Phase I/ II studies have led to Phase III trials in renal cell carcinoma and non-small cell lung that started patient recruitment in May 2000. To be eligible for enrollment into the Phase III clinical study of LCE in renal cell carcinoma, patients had to fulfill a set of strict conditions:

Main inclusion criteria

* Histologically confirmed renal cell adenocarcinoma

* At least one site of measurable metastatic disease

* Failure of IFN and/or IL-2 treatment received as first line regimen

* Progressive disease objectively documented within 16 weeks of the end of the first-line treatment regimen

* An ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1

(The ECOG performance status is used, on a scale of 0-5, to assess how the disease affects the daily activities of the patient. A patient with an ECOG of 0 is fully active, while a patient with an ECOG of 1 cannot perform physically strenuous activities but is otherwise functional)

Main exclusion criteria

* People with resectable metastasis

* People who were expected to receive additional therapies for RCC during the study

* People with allergy to fish

The study was designed to evaluate the efficacy of LCE in prolonging survival of patients with progressive metastatic renal cell carcinoma, refractory to standard immunotherapy. The randomized, double-blind, placebo-controlled trial was conducted in approximately 50 hospitals and clinical centers throughout Canada, the United States and Europe. Patient recruitment was completed in December 2001. Patients were stratified into four groups, according to their ECOG status (0 or 1) and the number of metastatic sites (1 or more than 1). Results from this clinical trial have been released in September 2003 and presented at the "Angiogenesis: New Opportunities & Solutions for Drug Development" meeting held on September 29-30, 2003 in Cambridge, Massachusetts.


A significant survival advantage was observed in one of the preplanned groups. Patients with stage IV clear cell RCC, an ECOG = 0, and one metastatic site who received LCE (n=21) doubled their median survival time increasing to 31.1 months compared to 15.0 months for the placebo group (n=17). The result was statistically significant, with a p value of (p= 0.046). As with previous studies, LCE showed an excellent safety profile with only 0.007% of the patients presenting an adverse event possibly related to LCE intake.


A randomized, double-blind, placebo-controlled phase III trial was conducted to determine the efficacy of LCE as monotherapy in metastatic RCC patients who had progressed following a first-line immunotherapy. Such patients usually display very poor prognosis with an estimated survival time of 8-12 months. The results evidenced a significant survival advantage for a cohort of patients with clear cell histology, an ECOG=0, and a single metastatic site. In clinical history, it is the first time ever that a group of patients with metastatic RCC refractory to the standard of treatment, showed statistically significant clinical benefits with a natural product. The fact that the increase in median survival time was seen in a group with an ECOG=0 and one metastatic site suggests that LCE should be given as early as possible to improve efficacy. The confirmed safety profile of LCE supports its use in prolonged therapeutic protocols.

Furthermore, based on prior antiangiogenesis trials in cancer and the knowledge emerging from basic research, patients should benefit even more from the use of LCE in first line combination therapies (Folkman, 2003). In the case of metastatic RCC protocols, LCE inclusion, through inhibition of MMP9 activity, has the potential to synergize with standard treatments consisting of IFN and/or IL-2. Indeed, MMP9 activation can cut short signaling events initiated by either IFN or IL-2. MMP9 can dimmer beneficial IFN action through the proteolytic degradation of IFN molecules, an effect that is prevented in the presence of an MMP inhibitor (Nelissen et al, 2003). MMP9 is also able to shed the receptor for IL-2 from the surface of cells, therefore interfering with the effects of the cytokine (Sheu et al, 2001). The inclusion of LCE in IFN and/or IL-2 cancer protocols may thus allow for the use of lower concentrations of these cytokines and contribute to reducing side-effects normally associated with these standard therapies in RCC.

Tumor development is the unfortunate result of cumulative deleterious molecular events calling for an orchestrated attack on several fronts. Being endowed with multiple activities, LCE fulfills the criteria to be a kind of "combination therapy" with a potential to synergize with existing anti-proliferative therapies to better fight cancer. LCE is emerging as a promising new polyvalent weapon in the anti-cancer armamentarium.


Rene Augstburger

Vice President, Sales and Marketing


Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol. 2002 Aug;13(8):1259-63.

Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pepin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res. 2002 Apr;8(4):1242-50.

Berbari P, Thibodeau A, Germain L, Saint-Cyr M, Gaudreau P, Elkhouri S, Dupont E, Garrel DR, Elkouri S. Elkhouri S, Antiangiogenic effects of the oral administration of liquid cartilage extract in humans. J Surg Res. 1999 Nov;87(1):108-13. Erratum in: J Surg Res 2000 Apr;89(2):197.

Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem. 1997 Jun 13;272(24):15496-500.

Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther. 2002 Aug;1(10):795-802.

Bukowski RM. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investing Drugs. 2003 Aug;12(8):1403-11. Review

Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003 Oct;4(5):385-90.

Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33.

Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Beliveau R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res. 2001 Jan-Feb;21(1A):145-55.

Gingras D, Labelle D, Nyalendo C, Boivin D, Demeule M, Barthomeuf C, and BEliveau R. The antiangiogenic agent Neovastat ([delta]-941) stimulates tissue-type plasminogen activator activity. Submitted

Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994 May;7(1):85-90.

Hagemann T, Gunawan B, Schulz M, Fuzesi L, Binder C. mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur J Cancer. 2001 Oct;37(15):1839-46.

Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol. 2000 Jan;163(1):343-7.

Junker K, Weirich G, Amin MB, Moravek P, Hindermann W, Schubert J. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res. 2003;162:169-75.

Kamiya N, Kishimoto T, Suzuki H, Sekita N, Nagai Y, Oosumi N, Kito H, Tochigi N, Shinbo M, Nemori R, Ichikawa T, Igarashi T, Ito H, Ishikura H. Increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion. Int J Cancer. 2003 Sep 10;106(4):480-5.

Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28;260(5112):1317-20.

Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E. Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat) in the Treatment of Non-Small-Cell Lung Cancer (submitted)

Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol. 2003 Aug;170(2 Pt 1):588-92.

Nelissen I, Martens E, Van den Steen PE, Proost P, Ronsse I, Opdenakker G. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain. 2003 Jun;126(Pt 6):1371-81.

Nor JE, Polverini PJ. Role of endothelial cell survival and death signals in angiogenesis. Angiogenesis. 1999;3(2):101-16.

Olson TM, Hirohata S, Ye J, Leco K, Seldin MF, Apte SS. Cloning of the human tissue inhibitor of metalloproteinase-4 gene (TIMP4) and localization of the TIMP4 and Timp4 genes to human chromosome 3p25 and mouse chromosome 6, respectively. Genomics. 1998 Jul 1;51(1):148-51.

Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, Ba N, Benoit G, Jardin A, Bedossa P. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch. 2000 Apr;436(4):351-6.

Sauder DN, Dekoven J, Champagne P, Croteau D, Dupont E. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol. 2002 Oct;47(4):535-41.

Shepherd FA, Sridhar SS Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer. 2003 Aug;41 Suppl 1:S63-72.

Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res. 2001 Jan-Feb;21(1A):145-55. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001 Jan 1;61(1):237-42.

Van den Steen PE, Husson SJ, Proost P, Van Damme J, Opdenakker G. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun. 2003 Oct 24;310(3):889-96.

Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning SA, Frei U, Maher ER, Grone HJ, Eckardt KU. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factorlalpha in clear cell renal carcinomas. Cancer Res. 2001 Jul 1;61(13):5215-22.

Zhang Q, Chen Z, Shi Z. Mechanisms of drug resistance of primary renal cell carcinomas and their clinical significance] Zhonghua Zhong Liu Za Zhi. 2000 Mar;22(2): 145-7.

by Dominique Garrel, MD, CSPQ, Professor of Medicine

Director, Department of Nutrition, University of Montreal

COPYRIGHT 2004 The Townsend Letter Group
COPYRIGHT 2004 Gale Group

Return to Von Hippel-Lindau disease
Home Contact Resources Exchange Links ebay